Founded in 2012 as a spin-off from Chalmers University of Technology in Sweden, Fluicell is a public biotech company specializing in high resolution bioprinting and single-cell biology. The company is a world leader and pioneer in open-volume microfluidics for the life sciences, and holds a strong IP and patent position with five different patent families in the estate.

The product portfolio consists of the 3D single-cell bioprinting platforms Biopixlar and Biopixlar AER and a product series for single-cell biological and pharmacological research, consisting of BioPen, Biozone 6 and Dynaflow Resolve.